[HTML][HTML] Determining and comparing the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in patients hospitalized with COVID-19
YR Jang, Y Oh, JY Kim - Journal of Korean Medical Science, 2024 - ncbi.nlm.nih.gov
Background Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
AJ Haddad, RY Hachem, M Moussa, Y Jiang… - Cancers, 2024 - mdpi.com
Simple Summary The results of previous studies may suggest that Nirmatrelvir/Ritonavir,
when evaluated against placebo controls, could potentially be more effective than …
when evaluated against placebo controls, could potentially be more effective than …
[PDF][PDF] Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?
JY Lee - Journal of Korean Medical Science, 2024 - jkms.org
Provisional be done with caution. However, subgroup analyses stratified by those aged≥ 65
years and those aged< 65 years, as well as subgroup analyses stratified by risk factors for …
years and those aged< 65 years, as well as subgroup analyses stratified by risk factors for …
Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study
X xiu Chen, X Yang, S Chen, M Yang, Z Yuan, R Chen… - 2024 - researchsquare.com
Objective This retrospective cohort study aimed to assess the clinical characteristics,
treatment outcomes, and short-term prognosis of kidney transplant recipients (KTRs) with …
treatment outcomes, and short-term prognosis of kidney transplant recipients (KTRs) with …